Adverse reactions and antibody response to an acellular pertussis toxoid vaccine in adult volunteers.
A monovalent pertussis toxoid vaccine (JNIH-7, Biken, Japan) was evaluated for reactogenicity and immunogenicity in 20 healthy adults (phase 1 study). Fever of greater than or equal to 38 degrees C was recorded in 2/20; local reactions started in 2/20 on day 1 (early onset) and in 3/20 on day 7 (late onset). All 15/15 subjects tested showed a significant antibody response to pertussis toxin by neutralization or enzyme-linked immunosorbent assay. Significantly elevated antibodies were still detected in 12/13 subjects 32 months after the single subcutaneous dose of vaccine.
Hederstedt
B
B
Department of Bacteriology, National Bacteriological Laboratory, Stockholm, Sweden.
Granström
M
M
D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis; D000917:Antibody Formation; D005260:Female; D005334:Fever / Q000209:etiology; D006801:Humans; D008297:Male; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000009:adverse effects* / Q000276:immunology; D011795:Surveys and Questionnaires; D010566:Virulence Factors, Bordetella / Q000276:immunology
D000907:Antibodies, Bacterial; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella; D037342:Pertussis Toxin